We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

BioMedomics Launches COVID-19 IgM-IgG Rapid Test for Novel Coronavirus

By LabMedica International staff writers
Posted on 14 Mar 2020
Print article
Image: COVID-19 IgM-IgG Rapid Test (Photo courtesy of BioMedomics, Inc.)
Image: COVID-19 IgM-IgG Rapid Test (Photo courtesy of BioMedomics, Inc.)
BioMedomics, Inc. (Morrisville, NC, USA) has developed and launched one of the world’s first rapid point-of-care lateral flow immunoassays for the diagnosis of coronavirus infection. The new rapid IgM-IgG combined antibody test for COVID-19 is used to qualitatively detect IgG and IgM antibodies of the novel coronavirus in human serum, plasma or whole blood in vitro. These proteins indicate that a person’s immune system has responded to infection with the COVID-19 virus. It is one of the world’s first rapid tests for coronavirus utilizing this technology.

Recent studies suggest that a high percentage of patients show no clinical symptoms of the virus, which makes screening patients vitally important. The test can be used for rapid screening of carriers of the virus that are symptomatic or asymptomatic. By using biomarkers from the body’s immune response to COVID-19 instead of looking for the virus itself, the test can help determine if a person has been infected with COVID-19 even after the virus is no longer present. This information helps experts to better understand how the virus spreads through populations and develop strategies to prevent and slow the epidemic. The test is ideally suited for hospitals, clinics and test laboratories, and can also be effectively deployed in businesses, schools, airports, seaports and train stations, etc.

BioMedomics’ new rapid IgM-IgG combined antibody test for COVID-19 has been used widely by the Chinese CDC to combat infections and is now available globally. BioMedomics has also received CE Mark-IVD certification for the test which will allow it to be used to help diagnose patients in areas of Europe that have been impacted by the appearance of the COVID-19 pathogen.

“We are very proud to help fight this global epidemic,” said Dr. Frank Wang, CEO of BioMedomics. “Our team has been working hard to make this test a reality in the hope that it can help millions of people around the world by providing health experts with the information that they need to help treat and contain this new virus.”

Related Links:
BioMedomics, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
COVID-19 Rapid Test
AQ+ COVID-19 Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more